Author

Peter Irving 1

1 Guy´s and St Thomas´ Hospital Dept. of Gastroenter

A NOVEL ORAL DOMAIN ANTIBODY TO TUMOUR NECROSIS FACTOR (TNF), ENGINEERED TO BE STABLE TO INTESTINAL PROTEASES, RESULTS IN HIGH CONCENTRATIONS OF ACTIVE COMPOUND DETECTED IN FAECES OF CROHN’S PATIENTS AFTER ORAL DOSING

Jan Robinson, Scott Crowe, Mike West, Tim Carlton, Luana Maggiore, Gary Whale, James Ritter, Peter Irving, Suhail Nurbhai

A PROTEASE-STABILISED ORAL DOMAIN ANTIBODY TO TNF DELIVERS HIGH CONCENTRATIONS OF ACTIVE COMPOUND IN ILEAL FLUID OF SUBJECTS WITH AN ILEOSTOMY

Jan Robinson, Scott Crowe, Gary Whale, Kevin Roberts, Mike West, James Ritter, Peter Irving, Suhail Nurbhai

A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE

James Lindsay, Alan J Lobo, John Snowden, Hannah Berntsson, Mike Bradburn, Lauren Desoysa, Shahida Din, John Gribben, Danny Hind, Ellen Lee, Yash Mahida, Gordon Moran, Peter Irving, Christopher John Hawkey, Miles Parkes, Lizzie Swaby, Simon Travis, Sree Subramanian, Jack Satsangi

BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Remo Panaccione, Irina Blumenstein, Peter Irving, Ramona Vladea, Dapo Ilo, Wen Zhou, Gweneth Levy, Xuan Yao, Iris Dotan

COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL

Sangwook Yoon, Dong-Hyeon Kim, Fraser Cummings, Peter Irving, Geert R. D'Haens, Shomron Ben-Horin, Walter Reinisch, Byong Duk Ye, Stefan Schreiber

Correlation of vedolizumab trough levels with clinical and biochemical markers in inflammatory bowel disease

Aravind Gokul Tamilarasan, Antonio Guerrero, Laura Arias, Megan Burns, Zehra Arkir, Susanna Meade, Peter Irving

COST-UTILITY OF BIOSIMILAR INFLIXIMAB (INFLECTRA©) FOR THE TREATMENT OF LUMINAL CROHN?S DISEASE IN NINE EUROPEAN COUNTRIES

Fanni Rencz, Valentin Brodszky, Petra Baji, Marta Pentek, Laszlo Gulacsi, Petra Anna Golovics, Zsuzsanna Vegh, Krisztina Barbara Gecse, Silvio Danese, Peter Irving, Peter L Lakatos

COST-UTILITY OF BIOSIMILAR INFLIXIMAB FOR THE TREATMENT OF FISTULISING CROHN?S DISEASE IN NINE EUROPEAN COUNTRIES

Petra Baji, Marta Pentek, Valentin Brodszky, Laszlo Gulacsi, Fanni Rencz, Petra Anna Golovics, Krisztina Barbara Gecse, Zsuzsanna Vegh, Silvio Danese, Peter Irving, Peter L Lakatos

COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE

James Alexander, Zhigang Liu, Diana Munoz Sandoval, Catherine Reynolds, Hajir Ibraheim, Sulak Anandabaskaran, Aamir Saifuddin, Rocia Castro Seoane, Nikhil Anand, Rachel Nice, Claire Bewshea, Andrea D'Mello, Laura Constable, Gareth R Jones, Sharmili Balarajah, Francesca Fiorentino, Shaji Sebastian, Peter Irving, Lucy Hicks

DIFFUSION WEIGHTED MRI OF INFLAMMATORY BOWEL DISEASE

Sarah Aurakzai, Sofia Gourtsoyianni, Simon H. Anderson, Peter Irving, Vicky Goh, Nyree Griffin, Jeremy Sanderson

Item 1 - 10 / 71
1
2 3 4 5 6 7 8